Farmas USA

Cellceutix Completes Clinical Trial of Kevetrin for Advanced Solid Tumors

BEVERLY, MA–(Marketwired – February 16, 2016) Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce the successful completion of its Phase 1 trial of Kevetrin in patients with advanced solid tumors conducted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center.

The open-label, dose escalation study met Cellceutix’s objectives by demonstrating the safety and tolerability of Kevetrin, while providing key information on the pharmacokinetics of Kevetrin. These data are being utilized in designing a Phase 2 study, which will evaluate Kevetrin as a component of combination therapy in the treatment of ovarian cancer. As disclosed on February 10, 2016, the U.S. Food and Drug Administration (FDA) informed Cellceutix that increasing the frequency of Kevetrin dosing from once weekly to three times weekly would be acceptable based upon the data from the Phase 1 study. We look forward to these future trials and are hopeful that Kevetrin will develop into one of the great cancer treatment drugs.

Cellceutix is developing Kevetrin under an Orphan Drug designation for ovarian cancer from the FDA.

Cellceutix would like to thank all the staff at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center for their tireless work and valuable insight throughout the clinical trial, especially the trial’s Principal Investigator, Dr. Geoffrey Shapiro. The trial was a success and we appreciate the opportunities recently afforded to us to further expand enrollment for the purpose of excellent research on Kevetrin for better patient care.

Cellceutix is now informing clinicaltrials.gov that the trial is no longer active and expects the website to be updated soon to reflect the trial as completed.

CTIX

Yo me he hecho una fotocopia aumentada de la puñetera tarjeta de coordenadas para localizar la coordenada lo mas rapido posible. La tengo pegada en la pared. Es insufrible ja,ja

Personalmente, si esto es un breakout de NVAX estare encantado. Pero prefiero recuperar la pasta. Que tengo mucha ya inmovilizada.

edito: y como le de al IBB por cerrar el hueco me voy a comprar las HZNP bien baratitas

IBB velas 30 minutos

Un gap de escape incluso una vuelta en isla, sería muy buena señal.

+10%, mucha polvora gastada, a ver como resuelve esto ...

NVAX

OTC

BT chicos, quiero ampliar con un tercer broker solo para OTC, que tenga todo el OTC disponible, y que cueste poco de comisiones. ¿Sabeis Solofarmas o alguno de vosotros un broker especializado en eso, BBB, jejeje?

Yo trabajo con IB, como ya sabes....

He subido la media de NVAX, seguramente me habré precipitado mucho, pero como he decidido tener unos cuantos cromos más, he pillado a $4,95. Ahora sí que creo que solo cargaré si se pone a $4 o un poco por encima. La otra sería vender todo ahora y esperar a comprar más baratas pero seguro que entonces se dispara :).

NVAX

A mi me parece precipitado comprar un stock cuando lleva un +8% en la primera media hora de apertura siendo ademas que no tiene ninguna new. Pero en cualquier caso llevas una media envidiable, Investing_saints, saldras bien parado. :)

NVAX